Company Overview
Escape Therapeutics, Inc. is an early stage biotechnology company focused on accelerating the commercial
availability of allogeneic stem cell therapies by solving the key translational hurdle preventing their
clinical utility - immune mismatch and subsequent donor rejection.
Invented by Escape's founder Dr. Hantash while at Stanford University, our platform technology represents
a significant potential breakthrough that can revolutionize the treatment of numerous medical diseases that
require cell and/or organ replacement such as type I diabetes, Parkinson's, and leukemia, amongst others.
Escape's innovative technology allows for the creation of the world's first allogeneic, "off-the-shelf"
therapy capable of being used in any patient irrespective of their HLA profile without the need for adjunctive
immunosuppression, HLA matching, or autologous sourcing.